Literature DB >> 22434757

Serum protein N-glycosylation in paediatric non-alcoholic fatty liver disease.

B Blomme1, E Fitzpatrick, A Quaglia, R De Bruyne, A Dhawan, H Van Vlierberghe.   

Abstract

OBJECTIVE: We have previously shown the potential of glycomics to distinguish patients with steatosis from patients with non-alcoholic steatohepatitis (NASH) in an adult population. The pattern of disease in paediatric patients is distinct from adults. The objective of this study was to characterize the N -glycomic profile of children with varying degrees of non-alcoholic fatty liver disease (NAFLD) and identify potential biomarker profiles of disease.
METHODS: Serum protein N-glycosylation patterns of 51 paediatric NAFLD patients were assessed with deoxyribonucleic acid sequencer-assisted fluorophore-assisted capillary electrophoresis and compared with histology.
RESULTS: Peak 1 (NGA2F) is the most significantly elevated N-glycan in paediatric NASH patients with peak 5 (NA2) demonstrating the largest decrease. The logarithmically transformed ratio of peak 1 to peak 5 was -0.85 (standard deviation [SD] 0.22) in patients with steatosis and borderline NASH and -0.73 (SD 0.12) in NASH (P = 0.02). The biomarker correlated well with the amount of lobular inflammation with a consistent increase of marker score in ascending stage of lobular inflammation. There was also a trend in differentiating patients with significant fibrosis ≥F2; -0.74 (SD 0.13) from patients with no/minimal fibrosis <F2; -0.86 (SD 0.24), P = 0.06. Analysis of the N-glycans on immunoglobulin G confirmed the undergalactosylation status typical for chronic inflammatory conditions.
CONCLUSIONS: This study is the first glycomic analysis performed in a paediatric NAFLD population. In agreement with the results obtained in adults, B cells play a dominant role in the N-glycan alterations of paediatric NASH patients.
© 2012 The Authors. Pediatric Obesity © 2012 International Association for the Study of Obesity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22434757     DOI: 10.1111/j.2047-6310.2011.00024.x

Source DB:  PubMed          Journal:  Pediatr Obes        ISSN: 2047-6302            Impact factor:   4.000


  7 in total

Review 1.  Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future.

Authors:  Emer Fitzpatrick; Anil Dhawan
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

2.  Identification of unique glycoisoforms of vitamin D-binding protein and haptoglobin as biomarker candidates in hepatocarcinogenesis of STAM mice.

Authors:  Yasunobu Yoshida; Jun-Ichi Furukawa; Shoichi Naito; Kenichi Higashino; Yoshito Numata; Yasuro Shinohara
Journal:  Glycoconj J       Date:  2018-09-08       Impact factor: 2.916

3.  Prevalence and outcome of non-alcoholic fatty liver disease in adolescents and young adults undergoing weight loss surgery.

Authors:  K E Corey; T L Stanley; J Misdraji; C Scirica; J Pratt; A Hoppin; M Misra
Journal:  Pediatr Obes       Date:  2014-03-27       Impact factor: 4.000

Review 4.  Advances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics.

Authors:  Simona Riccio; Rosa Melone; Caterina Vitulano; Pierfrancesco Guida; Ivan Maddaluno; Stefano Guarino; Pierluigi Marzuillo; Emanuele Miraglia Del Giudice; Anna Di Sessa
Journal:  World J Clin Pediatr       Date:  2022-03-23

Review 5.  Diagnostic management of nonalcoholic fatty liver disease: a transformational period in the development of diagnostic and predictive tools-a narrative review.

Authors:  Natalia Rosso; Adam M Stephenson; Pablo J Giraudi; Claudio Tiribelli
Journal:  Ann Transl Med       Date:  2021-04

Review 6.  The Continuum of Aging and Age-Related Diseases: Common Mechanisms but Different Rates.

Authors:  Claudio Franceschi; Paolo Garagnani; Cristina Morsiani; Maria Conte; Aurelia Santoro; Andrea Grignolio; Daniela Monti; Miriam Capri; Stefano Salvioli
Journal:  Front Med (Lausanne)       Date:  2018-03-12

7.  Triglyceride-Rich Lipoproteins and Glycoprotein A and B Assessed by 1H-NMR in Metabolic-Associated Fatty Liver Disease.

Authors:  Juan Moreno-Vedia; Roser Rosales; Enrique Ozcariz; Dídac Llop; Maribel Lahuerta; María Benavent; Ricardo Rodríguez-Calvo; Núria Plana; Angels Pedragosa; Lluís Masana; Antoni Castro; Daiana Ibarretxe; Josefa Girona
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-10       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.